Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis

G. Procopio, J. Bellmunt, J. Dutcher, S. Bracarda, J. Knox, A. Brueckner, I. Molnar, B. Escudier, T. E. Hutson

Research output: Contribution to journalArticlepeer-review

Abstract

Background:Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (

Original languageEnglish
Pages (from-to)311-318
Number of pages8
JournalBritish Journal of Cancer
Volume108
Issue number2
DOIs
Publication statusPublished - Feb 2013

Keywords

  • Elderly
  • Renal cell carcinoma
  • Sorafenib
  • Targeted therapies
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis'. Together they form a unique fingerprint.

Cite this